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Abstract
Background: Phase II studies have shown that the combination of capecitabine and irinotecan (the
XELIRI regimen) is active in metastatic colorectal cancer (MCRC). There are, however, no data
about the use of the XELIRI regimen in the neoadjuvant treatment.
Methods: Patients with unresectable liver-only metastases of MCRC with ≤ 75 years of age were
randomised to either the XELIRI (irinotecan 250 mg/m2 given on day one and capecitabine 1000
mg/m2 twice daily from day 2–15, every 21 days) or the FOLFIRI arm (irinotecan 180 mg/m2, 5-FU
400 mg/m2, LV 200 mg/m2, 5-FU 2400 mg/m2 (46-h infusion) – all given on day one, every 14 days).
Primary end points were objective response rate (ORR) and rate of radical (R0) surgical resection.
Secondary end points were progression-free survival (PFS), overall survival (OS) and safety.
Results: Altogether 87 patients were enrolled (41 pts in the XELIRI and 46 pts in the FOLFIRI
arm). The median age was 63 years (63 years in the XELIRI and 62 years in the FOLFIRI arm) (p =
0.33). ORR was 49% in the XELIRI and 48% in the FOLFIRI arm (p = 0.76). The rate of radical R0
resection was 24% in both arms of patients. At the end of treatment, 37% of patients in the XELIRI
and 26% of patients in the FOLFIRI arm were without evidence of the disease (CR+R0 resection)
(p = 0.56). There were no statistical differences in grade 3 or 4 adverse events between both arms:
diarrhoea 7% vs. 6%, neutropenia 5% vs. 13%, ischemic stroke 0 vs. 2%, acute coronary syndrome
2% vs. 4%, respectively. At the median follow up of 17 (range 1–39) months, the median PFS was
10.3 months in the XELIRI and 9.3 months in the FOLFIRI arm (p = 0.78), the median OS was 30.7
months in the XELIRI arm and 16.6 months in the FOLFIRI arm (p = 0.16).
Conclusion: The XELIRI regimen showed similar ORR as the FOLFIRI regimen in the neoadjuvant
treatment of patients with MCRC. In addition, the XELIRI regimen showed similar PFS and OS with
acceptable toxicity compared to the FOLFIRI regimen.
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Background
The majority of patients with metastatic colorectal cancer
(MCRC) have liver metastases. Radical (R0) resection of
liver metastases offers the greatest likelihood of cure in the
patients with liver-only metastases of MCRC. The five-year
survival rates after radical resection are 24–58% [1-4],
whereas the five-year survival rates for unresectable dis-
ease with most active systemic chemotherapy regimens
are <5% [5]. Since the majority of patients with MCRC
have unresectable liver metastases, neoadjuvant (or pre-
operative) chemotherapy is an appropriate treatment
choice with intent to reduce the number and/or size of the
liver metastases to make the radical (R0) resection of liver
metastases possible. This can be achieved in 12–33% of
patients [6-8]. In the neoadjuvant chemotherapy, combi-
nations of fluoropyrimidines (5-FU/leucovorin (LV))
with irinotecan and/or oxaliplatin are usually used.
Among the combinations of fluoropyrimidines with iri-
notecan, the FOLFIRI regimen is preferred, whereas the
FOLFOX regimen is preferred among the combinations of
fluoropyrimidines with oxaliplatin. Randomised studies
have shown that the combination of capecitabine with
oxaliplatin (XELOX regimen) in the first-line treatment of
patients with MCRC shows similar efficacy and tolerabil-
ity compared to the combinations of 5-FU/LV with oxali-
platin [9,10]. There are, however, only few published data
about the combination of capecitabine with irinotecan in
the treatment of patients with MCRC. Phase I/II studies
have demonstrated that the combination of capecitabine
(1000 mg/m2 twice daily for 14 days) with irinotecan
(250 mg/m2 i.v. on day one, every 21 days) (the XELIRI
regimen) is active [11-14]. The XELIRI regimen showed
response rates of 35–54% and time to progression 8–9
months. Most common treatment-related grade 3 or grade
4 adverse events reported from a phase II study were neu-
tropenia (25%), diarrhoea (20%), vomiting (16%), dehy-
dration (10%), nausea (6%), abdominal pain (6%), and
hand-foot syndrome (6%) [11].
To our knowledge, there has been no study published
with the XELIRI regimen in the neoadjuvant setting of
patients with unresectable liver-only metastases of MCRC.
The aim of our study was to compare the efficacy, safety
and survival of the XELIRI regimen to the standard FOLF-
IRI regimen in the neoadjuvant setting of patients with
unresectable liver-only metastases of MCRC.
Our hypothesis was that there are no statistically signifi-
cant differences in efficacy, survival and safety of the
XELIRI regimen compared to the standard FOLFIRI regi-
men. However, the XELIRI regimen seems to be more con-
venient when compared to the FOLFIRI regimen since
capecitabine is an oral drug; therefore, there is no need for
central venous catheters implantation (risk for bleeding,
infection, thrombosis) and no need for hospitalisation.
The treatment is performed in out-patient clinic. The
cycles are applied every 21 days compared to every 14
days in the FOLFIRI regimen.
In the year 2004, at the time when our study was initiated,
bevacizumab was not yet registered for the treatment of
patients with MCRC in Slovenia. However, in 2006, while
our study was ongoing, bevacizumab became a standard
in the first-line treatment of patients with MCRC. This was
the main reason why the study was prematurely closed for
the accrual at the end of the year 2006 with only 43% of
initially planned accrual.
Methods
The study was performed at the Institute of Oncology
Ljubljana, Slovenia, after it had been approved by
National Medical Ethics Committee. This was a prospec-
tive randomised phase II study.
Eligibility criteria were: age 18–75 years, performance sta-
tus of 0–1 according to WHO, unresectable liver metas-
tases of colorectal adenocarcinoma – determined by liver
surgeon either because of the size, number, or unfavoura-
ble location of metastases that did not allow a complete
resection of disease leaving at least 25% of normal liver
parenchyma, no prior chemotherapy for metastatic dis-
ease, >6 months since adjuvant treatment, at least one
measurable lesion of ≥ 1 cm visible on spiral computed
tomography (CT), bilirubin < 2× times the upper limit of
normal (ULN), aspartate aminotransferase (AST) < 5×
ULN, alanine aminotransferase (ALT) < 5× ULN, adequate
haematological and renal function, and signed informed
consent.
Exclusion criteria were: extra-hepatic disease (either metas-
tases outside liver or loco-regional recurrence), other
malignancy within the past 5 years (except limited basal
cell or squamous cell carcinoma of the skin or in situ cer-
vical carcinoma), inadequately controlled hypertension
(blood pressure >150/100 mmHg on antihypertensive
medications), unstable angina pectoris, history of myo-
cardial infarction or stroke within 6 months, clinically sig-
nificant peripheral vascular disease, inflammatory bowel
disease. Patients that fulfilled eligibility criteria were ran-
domly assigned to either the XELIRI or FOLFIRI arm with
no prior stratification.
Patient evaluation
Pre-treatment evaluation included a detailed medical his-
tory, physical examination, a complete blood count with
differential and platelet count, blood chemistry, serum
levels of carcinoembryonic antigen (CEA) and baseline
tumour measurements by CT. The pre-treatment evalua-
tion had to be performed within 14 days before the treat-
ment was initiated. The patients were assessed for toxicityBMC Cancer 2009, 9:120 http://www.biomedcentral.com/1471-2407/9/120
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before each application of cytotoxic drugs. Repeat imag-
ing was required every three months during treatment.
Chemotherapy was discontinued prior to the expiry of six
months if liver metastases became resectable (patients
were referred to liver surgeon) or if there was either pro-
gression of the disease or serious adverse event occurred
during chemotherapy. After the discontinuation of study
treatment, a follow-up examination, including clinical
examination, blood samples (liver enzymes, CEA), CT or
ultrasound of the abdomen, was performed every 3
months, until the progression of the disease or death.
Chemotherapy
The XELIRI regimen consisted of irinotecan 250 mg/m2
given on day one and capecitabine 1000 mg/m2 twice
daily from day 2–15, every 21 days. The FOLFIRI regimen
consisted of irinotecan 180 mg/m2, 5-FU 400 mg/m2, LV
200 mg/m2, 5-FU 2400 mg/m2 (46-h infusion) – all given
on day one, every 14 days. The patients in both arms
received premedication with dexamethason 20 mg i.v.,
granisetron 1 mg i.v. and diazepam 10 mg i.v. on day 1 of
each chemotherapy cycle. To initiate a cycle of cytotoxic
chemotherapy, an absolute neutrophil count of at least
1500/μl, platelets at least 100000/μl and resolution of
other toxic effects to at least CTC grade 1 were required. A
resolution of toxicity to at least CTC grade 1 was required
within 3 weeks of the intended start of a cycle or patients
were withdrawn from the study. All patients were advised
to use emollients with urea to manage hand-foot syn-
drome of grade I and II. The maximum planned duration
of the treatment was six months in both arms. Postopera-
tive chemotherapy was not planned.
Surgery
At evaluation, surgical resection of metastases was recon-
sidered by a team of experts, consisting of a liver surgeon,
radiologist and medical oncologist. Liver surgery was
attempted when technically feasible and potentially cura-
tive in the patients fit for operative procedure. During sur-
gery, a complete exploration of the abdomen, including
intraoperative ultrasound, was performed. Different surgi-
cal techniques were used for the resection of metastases.
The primary end points were: overall objective response
(ORR) and rate of radical surgical resection (R0 resection).
The evaluation of response was based on RECIST [15]. The
radical surgical resection (R0 resection) of liver metastases
was defined as tumour-free margin of >10 mm at histol-
ogy specimen and no signs of residual metastases during
exploration of the abdomen. In case of complete response
(CR), liver surgery was not performed; regular follow-up
was performed in these patients.
Secondary end points were: progression-free survival (PFS),
overall survival (OS) and safety. PFS was defined as the
time between the randomisation and the progression of
the disease or death of any cause; the patients who were
withdrawn from the study treatment for other reasons
were censored at the discontinuation of study therapy. OS
was defined as the time between the randomisation and
death. Treatment-related death was defined as the death
within 30 days after the last cycle of chemotherapy or liver
surgery. All toxic effects were graded according to the
National Cancer Institute (NCI) – Common Toxicity Cri-
teria (CTC), version 3.0. The histology reports docu-
mented any signs of steatohepatitis.
Statistical considerations
For the statistical power calculation, online DSS Research
toolkit was used. For the FOLFIRI arm, a response rate of
40% and a R0 resection rate of 15% was expected. The sta-
tistical power for initially planned 200 patients, with
Alpha Error level of 5% (a 95% Confidence Interval) to
show 10% difference between arms, was calculated to be
41% for the objective response rate, and 55% for the R0
resection rate. With 87 patients enrolled, the statistical
power for the objective response rate was 24%, and for the
R0 resection rate 32%.
Statistical analysis was performed with the program SPSS
– Version 1.3. For the comparison of the two arms, two-
sided Pearson chi-square test and Student's t-test were
used. Objective response rate was assessed on intention to
treat (ITT) population. Safety analysis was performed on
the group of patients who received at least one dose of
protocol medication. Overall survival and progression-
free survival were estimated according to Kaplan-Meier
method [16]. Survival curves were compared with the log-
rank test. Statistical difference between the arms was
determined as p < 0.05.
Results
In the period of 1 January 2004 – 31 December 2006,
altogether eighty-seven patients were enrolled. Forty-one
patients were randomly assigned to the XELIRI and forty-
six patients to the FOLFIRI arm. There were no statistically
significant differences in baseline characteristics between
the two arms (Table 1). Median duration of neoadjuvant
treatment was 5.0 (range 1.1 – 9.6) months in the XELIRI
arm and 5.1 (range 0.1 – 9.7) in the FOLFIRI arm (p =
0.45). The median follow up was 17 months (range 1–
39). The efficacy of both treatment arms (ORR, R0 resec-
tion rate) is shown in Table 2. At the time of evaluation by
CT scans after the conclusion of neoadjuvant chemother-
apy, the disease was expected to be resectable in 29% of
patients in the XELIRI arm and in 44% of patients in the
FOLFIRI arm (p = 0.16). All of these patients underwent
surgery. The R0 resection has been performed in 10 (24%)
of all patients in the XELIRI arm and in 11 (24%) of all
patients in the FOLFIRI arm (p = 0.83).BMC Cancer 2009, 9:120 http://www.biomedcentral.com/1471-2407/9/120
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Table 1: Baseline clinical characteristics of patients in the XELIRI and FOLFIRI arms, data are shown as n (%) or as n (range)
XELIRI FOLFIRI
n = 41 n = 46 p
Median age-years 63 (47–75) 62 (34–75) 0.33
Gender
Male 26 (63%) 27 (59%) 0.38
Female 15 (37%) 19 (41%) 0.40
WHO performance status
Performance status 0 31 (75%) 36 (78%) 0.82
Performance status 1 10 (25%) 10 (22%) 0.85
Primary tumour
Colon 30 (73%) 40 (87%) 0.23
Rectum 11 (27%) 6 (13%) 0.22
Initial stage of disease at diagnosis
Stage 1 01  ( 2 % ) -
Stage 2 7 (17%) 3 (7%) 0.21
Stage 3 6 (15%) 14 (30%) 0,07
Stage 4 28 (68%) 28 (61%) 1.0
Previous adjuvant treatment*
Yes 6 (15%) 10 (22%) 0.32
No 35 (85%) 36 (78%) 0.91
Median time from diagnosis to randomisation (months) 1.87 (0.7–65.5) 2.1 (0.26–55.7) 0.77
Number of liver metastases
1 – 4 15 (37%) 11 (24%) 0.43
5 – 10 8 (19%) 10 (22%) 0.81
> 10 18 (44%) 25 (54%) 0.28
Liver involvement (%)
< 25 14 (34%) 10 (22%) 0.41
25 – 50 13 (32%) 14 (30%) 0.85
> 50 14 (34%) 21 (45%) 0.24
Median size of liver metastases (cm) 4.0 (1.5 – 12.4) 5.0 (0.5–15.0) 0.10
Bilateral liver metastases, n (%) 35 (85%) 37 (80%) 0.81
Baseline CEA
Normal 8 (19%) 10 (22%) 0.64
> 3.5 μg/l 33 (81%) 36 (78%) 0.72
Baseline LDH
Normal 25 (61%) 18 (39%) 0.28
> 4.12 μkat/l 15 (37%) 26 (56%) 0.09
Reasons for initial unresectability
Location of metastases 10 (24%) 8 (17%) 0.52
Number of metastases 25 (61%) 30 (65%) 0.71
Size of metastases 6 (15%) 8 (17%) 0.84
* Adjuvant treatment with chemotherapy ± radiotherapy
Table 2: Efficacy of treatment in the XELIRI and FOLFIRI arms (response rate, R0 resection* rate), data are shown as n (%)
XELIRI FOLFIRI
n = 41 n = 46 p
Complete response 5 (12%) 1 (2%) 0.10
Partial response 15 (37%) 21 (46%) 0.32
Objective response 20 (49%) 22 (48%) 0.76
Stagnation 12 (29%) 10 (22%) 0.67
Progressive disease 7 (17%) 11 (24%) 0.35
R0 resection* 10 (24%) 11 (24%) 0.83
Complete response + R0 resection 15 (37%) 12 (26%) 0.56
R0 resection* – > 10 mm tumour-free resection margin on histologyBMC Cancer 2009, 9:120 http://www.biomedcentral.com/1471-2407/9/120
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The PFS of patients in the XELIRI and FOLFIRI arms is
shown in Figure 1. The median PFS for the patients in the
XELIRI arm was 10.3 months (95% CI: 9.1–11.5) and 9.3
months (95% CI: 6.7–12.0) in the FOLFIRI arm (p =
0.78). The OS of patients in the XELIRI and FOLFIRI arms
is shown in Figure 2. The median OS for the XELIRI arm
was 30.7 months (95% CI: 19.5–41.9) and for the FOLF-
IRI arm 16.6 months (95% CI: 7.9–25.3) (p = 0.16).
At the time of the analysis, of 21 patients who underwent
R0 resection of liver metastases, 19 (90%) were alive: in
the XELIRI arm, 9 out of 10 (90%) patients, and in the
FOLFIRI arm, 10 out of 11 (91%) (p = 0.82). At the time
of the analysis, CR after chemotherapy was evident in 4
out of 6 (67%) patients: in the XELIRI arm, 3 out of 5
(60%) patients, and in the FOLFIRI arm, 1/1 patient (p =
0.32).
Adverse events of any grade in the treatment the XELIRI
and FOLFIRI arms are shown in Table 3. The majority of
adverse events were of grade I or II. The adverse events of
grade 3 or 4 in the XELIRI arm were diarrhoea (7%), neu-
tropenia (5%), and acute coronary syndrome (2%). In the
FOLFIRI arm, the adverse events of grade 3 or 4 were neu-
tropenia (13%), diarrhoea (6%), acute coronary syn-
drome (4%), and ischemic stroke (2%). No hand-foot
syndrome of grade 3 occurred in any of the two arms.
Dose reduction due to adverse events was required in 12%
of patients in the XELIRI arm and in 22% of patients in the
FOLFIRI arm (p = 0.20). The therapy was completed as
planned in 90% of patients in the XELIRI arm and in 87%
of patients in the FOLFIRI arm (p = 0.85). The diagnosis
of steatohepatitis from histology reports at liver surgery
was present in 6/12 (50%) of patients in the XELIRI arm
and in 8/20 (40%) of patients in the FOLFIRI arm (p =
The PFS of patients in the XELIRI and FOLFIRI arms (months) Figure 1
The PFS of patients in the XELIRI and FOLFIRI arms (months).BMC Cancer 2009, 9:120 http://www.biomedcentral.com/1471-2407/9/120
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0.59). Steatohepatitis was present in median of 65%
(range 20% – 90%) of liver tissue in the XELIRI arm and
in median of 55% (range 10% – 70%) in the FOLFIRI arm
(p = 0.59). The intensity of steatohepatitis was either mild
(3 patients) or modest (3 patients) in the XELIRI arm, and
mild (5 patients), modest (1 patient) and severe (2
patients) in the FOLFIRI arm (p = 0.30). None of patients
with steatohepatitis had any additional perioperative co-
morbidity after liver surgery. There were no treatment-
related deaths in any of the two arms of patients.
At relapse, all patients received at least one line of chemo-
therapy: oxaliplatin-based second-line therapy received
85% of patients in the XELIRI arm and 62% of patients in
the FOLFIRI arm (p = 0.59), cetuximab-based second-line
therapy received 5% of patients in the XELIRI arm and
12% of patients in the FOLFIRI arm (p = 0.32).
Discussion
The present study reports the comparison of efficacy,
safety and survival between the XELIRI and FOLFIRI regi-
men in the neoadjuvant treatment of patients with MCRC.
The current single-institution randomised phase II trial
demonstrated that the XELIRI regimen is effective in the
neoadjuvant treatment of patients with MCRC and that it
has acceptable toxicity, when compared to the FOLFIRI
regimen. Both primary end-points were practically identi-
cal between the two arms. The relatively high rate of objec-
tive response (49% and 48%) in both arms is in the range
of expected, since all patients had liver-only metastases.
The rate of R0 resection (24%) of liver metastases in our
study is one of the highest reported. We believe that both
chemotherapy regimens are effective since, at the end of
treatment, 37% of patients were without any evidence of
the disease (either complete remission achieved with
chemotherapy or R0 resection of liver metastases) in the
XELIRI regimen and 26% of patients in the FOLFIRI regi-
men.
The OS of patients in the XELIRI and FOLFIRI arms (months) Figure 2
The OS of patients in the XELIRI and FOLFIRI arms (months).BMC Cancer 2009, 9:120 http://www.biomedcentral.com/1471-2407/9/120
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The PFS of 9–10 months in the patients in our study was
similar to the PFS of patients with liver only metastases
treated with the FOLFIRI regimen in a recently reported
large randomised the CRYSTAL trial [17]. In the CRYSTAL
trial, however, the secondary resection rate of liver metas-
tases in 134 patients with liver-only metastases was only
4.5%. Since the majority of patients in the CRYSTAL trial
had extra-hepatic disease, it is possible that the low rate of
secondary resection of liver-only metastases was due to
the lack of active searching for resectable liver metastases
after neoadjuvant chemotherapy by the multidisciplinary
team consisting of a liver surgeon, radiologist and medical
oncologist. We believe that this multidisciplinary
approach is essential for an optimal treatment outcome of
patients with liver-only metastases of MCRC.
Despite the high R0 resection rate in both our study arms
and high survival of patients following R0 resection in our
study, the median OS of all patients in the FOLFIRI arm is
one of the lowest ever reported for this regimen (16.6
months). It is possible that poor median OS in our FOLF-
IRI arm is due to the fact that only 62% of patients in this
arm received an oxaliplatin-based second line regimen at
progression of the disease. For the patients with MCRC
who receive all three chemotherapeutic drugs (irinotecan,
oxaliplatin, and fluoropyrimidine), the expected median
OS is 20–22 months [18,19].
It is noteworthy that the XELIRI regimen showed accepta-
ble toxicity. To our surprise, no grade 3 hand-foot syn-
drome, a well-known adverse event of capecitabine,
occurred in the XELIRI arm. This is possibly due to the
lower daily dose of capecitabine in the XELIRI regimen
than in the capecitabine monotherapy. During the treat-
ment with irinotecan and capecitabine, diarrhoea is a fre-
quent adverse event when these drugs are used as single
agents. In our study, the rate of grade 3 or 4 diarrhoea in
the XELIRI arm was also low. This is in concordance with
the European CAIRO trial [20], which showed no addi-
tional grade 3 or 4 diarrhoea in the patients in the XELIRI
arm as compared to the sequential therapy with capecitab-
ine and irinotecan monotherapy. In contrast, in the
recently published American trial BICC-C [21], the inci-
dence of grade 3 or 4 diarrhoea was present in 48% of
patients in the XELIRI arm. The reason for these differ-
ences in diarrhoea incidences among these trials is not
known.
The neoadjuvant chemotherapy is known to cause liver
toxicity. For the irinotecan-based regimens, the usual
pathological abnormality of liver cells is steatohepatitis.
Because of liver toxicity, the resection of liver metastases
should be performed as soon as the metastases become
resectable with neoadjuvant chemotherapy. There were
signs of steatohepatitis in both arms of patients, but no
additional co-morbidities were observed after liver resec-
tions in the patients of either arm.
In the recent years, three targeted drugs became available
for the treatment of patients with MCRC (bevacizumab,
cetuximab, panitumumab). Since best clinical benefit of
these drugs is achieved in combination with chemother-
apy, they are usually used with different chemotherapy
regimens. The combination of targeted therapy with dif-
ferent chemotherapy regimens showed favourable objec-
tive response rates when compared to chemotherapy
alone in phase II/III studies [17,22]. In the neoadjuvant
setting, the regimens with higher objective response rates
are preferred as it is believed that higher objective
response rates lead to higher R0 resection rates of liver
metastases. Therefore, the combination of targeted agents
with chemotherapy is generally applied in the neoadju-
vant setting. Because of this, our study was prematurely
closed soon after bevacizumab had become available in
our country. We believe that the XELIRI regimen should
be considered to be part of phase II trials where the tar-
geted drugs, like cetuximab or bevacizumab, are used in
Table 3: Adverse events regarding CTCAE-3 in the XELIRI and 
FOLFIRI arms, data are shown as n (%)
XELIRI FOLFIRI
N = 41 n = 46 p
Hand-foot syndrome
Grade 1 4 (10%) 0 0.18
Grade 2 2 (5%) 0 0.10
Grade 3 0 0 -
Diarrhoea
Grade 1 1 (2%) 4 (8%) 0.18
Grade 2 4 (10%) 7 (15%) 0.37
Grade 3 1 (2%) 2 (4%) 0.56
Grade 4 2 (5%) 1 (2%) 0.56
Nausea
Grade 1 3 (7%) 8 (17%) 0.13
Grade 2 6 (15%) 1 (2%) 0.06
Grade 3 0 0 -
Grade 4 0 0 -
Fatigue
Grade 1 3 (7%) 4 (9%) 0.70
Grade 2 1 (2%) 2 (4%) 0.56
Grade 3 0 0 -
Grade 4 0 0 -
Neutropenia
Grade 1 3 (7%) 2 (4%) 0.65
Grade 2 2 (5%) 12 (26%) 0.008
Grade 3 1 (2%) 5 (11%) 0.10
Grade 4 1 (2%) 1 (2%) 1.0
Thrombopenia of any grade 00 -
Ischemic stroke 01  ( 2 % ) -
Acute coronary syndrome 1 (2%) 2 (4%) 0.56
Death* 00 -
* Patients who died within 30 days after the last cycle of 
chemotherapy or liver surgeryBMC Cancer 2009, 9:120 http://www.biomedcentral.com/1471-2407/9/120
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combination with chemotherapy. Outside clinical trials,
in small subset of patients, where the targeted agents are
contraindicated or not available to the patients, the
XELIRI regimen could be used as an alternative to the
FOLFIRI regimen in the neoadjuvant setting of patients
with liver-only metastases of MCRC.
Conclusion
Our study showed that the XELIRI regimen is effective
with acceptable toxicity when compared to the FOLFIRI
regimen in neoadjuvant treatment of patients with unre-
sectable liver-only metastases of MCRC. XELIRI regimen
merits further evaluation in phase II trials in combination
with targeted drugs in patients with MCRC.
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